Patents by Inventor Daniel Jon Sall

Daniel Jon Sall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • sPLA2 inhibitors
    Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Spla2 inhibitors
    Patent number: 6916840
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • 3-substituted oxindole ?-3 agonists
    Patent number: 6911463
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • sPLA2 inhibitors
    Patent number: 6872743
    Abstract: A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 29, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
    Publication number: 20040254374
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 1, 2004
    Publication date: December 16, 2004
    Inventors: Stuart Donald Jones, Daniel Jon Sall, Michael Robert Wiley
  • Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
    Publication number: 20040249155
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 1, 2004
    Publication date: December 9, 2004
    Inventors: Michael Robert Wiley, Daniel Jon Sall, Christopher William Murray, Stephen Clinton Young, Jolie Anne Bastian
  • Chemical compounds
    Publication number: 20040249151
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 1, 2004
    Publication date: December 9, 2004
    Inventors: Steven Douglas Hiscock, Stuart Donald Jones, Daniel Jon Sall, Stephen Clinton Young, Michael Robert Wiley
  • 3-substituted oxindole beta-3 agonists
    Publication number: 20040242668
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: February 11, 2004
    Publication date: December 2, 2004
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Beta3 adrenergic agonists
    Publication number: 20040242633
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula I: 1
    Type: Application
    Filed: May 4, 2004
    Publication date: December 2, 2004
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Gerd Ruehter, Daniel Jon Sall, Theo Schotten, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • 3-Substituted oxindole &bgr; 3 agonists
    Patent number: 6825220
    Abstract: The present invention relates to a &bgr;;3 adrenergic receptor agonist of formula I: (1); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Cynthia Darshini Jesudason, Daniel Jon Sall, Freddie Craig Stevens, John Arnold Werner
  • Cyclohept'b!indole derivatives as spla2 inhibitors
    Publication number: 20040198801
    Abstract: 1
    Type: Application
    Filed: January 15, 2004
    Publication date: October 7, 2004
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • 3-Substituted oxindole beta 3 agonists
    Publication number: 20040097532
    Abstract: The present invention relates to a &bgr;;3 adrenergic receptor agonist of formula I: (I); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
    Type: Application
    Filed: April 11, 2003
    Publication date: May 20, 2004
    Inventors: Cynthia Darshini Jesudason, Daniel Jon Sall, Freddie Craig Stevens, John Arnold Werner
  • Novel spla2 inhibitors
    Publication number: 20040092543
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: May 13, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin Jr, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • &bgr;3 adrenergic agonists
    Patent number: 6730792
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • Novel spla2 inhibitors
    Publication number: 20040077704
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 22, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063941
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • Novel spla2 inhibitors
    Publication number: 20040063967
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Substituted tricyclics
    Patent number: 6713645
    Abstract: A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Susan Elizabeth Draheim, Robert Delane Dillard, Edward David Mihelich, Jason Scott Sawyer, Douglas Wade Beight, Michael LeRoy Phillips, Tulio Suarez, Daniel Jon Sall, Jolie Anne Bastian, Michael Lyle Denney, Gary Alan Hite, Michael Dean Kinnick, Robert Theodore Vasileff, John Michael Morin, Jr., Ho-Shen Lin, Michael Enrico Richett, Richard Waltz Harper, John McNeill McGill, III, Benjamin Alan Anderson, Nancy Kay Harn, Richard James Loncharich, Richard Walter Schevitz
  • Spla2 inhibitors
    Publication number: 20040059130
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Beta3 adrenergic agonists
    Publication number: 20030191156
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Application
    Filed: December 13, 2002
    Publication date: October 9, 2003
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner